A Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
Phase of Trial: Phase I/II
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Meningeal carcinomatosis
- Focus Adverse reactions; Therapeutic Use
- 19 Sep 2018 Planned End Date changed from 1 Apr 2022 to 30 Apr 2020.
- 19 Sep 2018 Planned primary completion date changed from 1 Apr 2021 to 30 Apr 2020.
- 02 May 2018 Status changed from not yet recruiting to recruiting.